6533b85afe1ef96bd12b9ec4

RESEARCH PRODUCT

Blastic Plasmacytoid Dendritic Cell Neoplasm

Eric DeconinckTony PetrellaFrancine Garnache Ottou

subject

Pathologymedicine.medical_specialtyMyeloidbusiness.industryLineage markersHematologyBlastic plasmacytoid dendritic cell neoplasm3. Good health03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureImmunophenotypingOncology030220 oncology & carcinogenesisMedicineImmunohistochemistryInterleukin-3 receptorBone marrowPresentation (obstetrics)business030215 immunology

description

Clinical and biological presentation of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) is depicted to highlight criteria that might alert physicians. Diagnosis of BPDCN is still challenging and requires (1) immunophenotyping of blood or bone marrow aspiration using several markers (CD4, CD56, HLA-DR, myeloid and lymphoid lineage markers) and should include pDC markers such as CD123, cTCL1, CD303, and CD304, and/or (2) pathologic analysis of cutaneous lesions, also with immunohistochemistry using markers specific to BPDCN.

yearjournalcountryeditionlanguage
2020-06-01Hematology/Oncology Clinics of North America
https://doi.org/10.1016/j.hoc.2020.01.010